A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Arnold, Emily A ^a   Hazelton, Patrick ^a   Lane, Tim ^a   Christopoulos, Katerina A ^b   Galindo, Gabriel R ^a   Steward, Wayne T ^a   Morin, Stephen F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

AMBULATORY CARE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMMUNITY LIVING; DRUG COST; DRUG DOSE REGIMEN; FOLLOW UP; FUNDING; GENERAL PRACTITIONER; HEALTH AUXILIARY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFORMATION DISSEMINATION; MALE HOMOSEXUAL; MEDICAL SPECIALIST; PATIENT ATTITUDE; PATIENT CARE; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PREEXPOSURE PROPHYLAXIS; PRESCRIPTION; PUBLIC RELATIONS; QUALITATIVE RESEARCH; SOCIAL SUPPORT; THINKING; TRANSSEXUALISM; TREATMENT RESPONSE; UNITED STATES;

ANTI-HIV AGENTS; CALIFORNIA; CHEMOPREVENTION; FEMALE; HEALTH PERSONNEL; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; MALE; QUALITATIVE RESEARCH; QUESTIONNAIRES; REFERRAL AND CONSULTATION; REIMBURSEMENT MECHANISMS;

EID: 84863821839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040603     Document Type: Article

References (30)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
2. Grant RM, (2010) Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 50: S96-101.
3. Michael NL, (2010) Oral preexposure prophylaxis for HIV-another arrow in the quiver? N Engl J Med 363: 2663-2665.
4. Cahill S, (2012) Pre-Exposure Prophylaxis for HIV Prevention: Moving toward Implementation. Boston, MA: The Fenway Institute.
5. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR, (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
6. Baeten J, Donnell D, Ndase P, Mugo N, Mujugira A, et al. (2012) ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women; Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
7. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, et al. (2012) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study; IAS Conference on HIV Pathogensis, Treatment and Prevention, Rome, Italy.
8. CDC (2011) Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 60: 65-68.
9. Grady D, (2012) F.D.A. Advisory Panel Backs Preventive Use of H.I.V. Drug. New York Times. Global Edition ed. New York NY.
10. MSN Money, (2012) U.S. FDA Grants Priority Review for Truvada® for Reducing the Risk of Acquiring HIV Infection.
11. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH, (2010) Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep 7: 210-219.
12. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K, (2010) Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice. J Acquir Immune Defic Syndr 55: 8-13.
13. Myers GM, Mayer KH, (2011) Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 25: 63-71.
14. Buchbinder SP, Liu A, (2011) Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 15: S72-79.
15. Kelesidis T, Landovitz RJ, (2011) Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 8: 94-103.
16. Leibowitz AA, Parker KB, Rotheram-Borus MJ, (2011) A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health 101: 982-985.
17. Hurt CB, Eron JJ Jr, Cohen MS, (2011) Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 53: 1265-1270.
18. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
19. Hazelton P, (2011) Financing and Delivery Mechanisms to Increase Pre-Exposure Prophylaxis (PrEP) Access in Populations at High-Risk of HIV Infection. San Francisco: Project Inform. 1-32 p.
20. Pazella E, (2011) Comments by Ed Pazella of Aetna at Safety Issues in Pre-exposure Prophylaxis for HIV Negative Individuals, Proposals for Management of Safety Concerns, and Pending Plans for Scale-up; Washington, DC.
21. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, et al. (2011) Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 22: 256-262.
22. Miles MB, Huberman AM, (1994) Qualitative Data Analysis: An Expanded Sourcebook: Sage Publications.
23. Patton MQ, (2002) Qualitative Research & Evaluation Methods: Sage Publications.
24. Muhr T, (1997) ATLAS.ti 5: The Knowledge Workbench. Berlin: Scientific Software Development.
25. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
26. Flash C, Krakower D, Mayer KH, (2012) The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep.
27. Marks G, Crepaz N, Janssen RS, (2006) Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20: 1447-1450.
28. Prejean J, Song R, Hernandez A, Ziebell R, Green T, et al. (2011) Estimated HIV incidence in the United States, 2006-2009. PLoS One 6: e17502.
29. Forsyth AD, Valdiserri RO, (2012) Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Curr Opin HIV AIDS 7: 111-116.
30. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.